Inovio Pharmaceuticals (INO) Total Non-Current Liabilities (2010 - 2022)

Inovio Pharmaceuticals has disclosed Total Non-Current Liabilities across 13 years of filings, most recently posting $126.2 million for Q4 2022.

• In Q4 2022, Total Non-Current Liabilities rose 31.08% year-over-year to $126.2 million; the TTM figure through Dec 2022 stood at $126.2 million (up 31.08% YoY), while the FY2022 annual figure was $126.2 million, up 31.08% from the prior year.
• Total Non-Current Liabilities came in at $126.2 million for Q4 2022 at Inovio Pharmaceuticals, up from $124.6 million in the prior quarter.
• In the past five years, Total Non-Current Liabilities ranged from a high of $161.7 million in Q2 2022 to a low of $36.9 million in Q3 2018.
• Average Total Non-Current Liabilities over 5 years is $96.7 million, with a median of $102.4 million recorded in 2019.
• Year-over-year, Total Non-Current Liabilities jumped 200.67% in 2019 and sank 43.27% in 2021.
• Over 5 years, Total Non-Current Liabilities stood at $44.0 million in 2018, then jumped by 194.88% to $129.7 million in 2019, then plunged by 39.43% to $78.6 million in 2020, then increased by 22.51% to $96.3 million in 2021, then soared by 31.08% to $126.2 million in 2022.
• Per Business Quant data, the three most recent Total Non-Current Liabilities figures were $126.2 million in Q4 2022, $124.6 million in Q3 2022, and $161.7 million in Q2 2022.